Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Bergenbio ASA (BGBIO)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
0.15 -0.01    -3.59%
26/04 - Closed. Currency in NOK ( Disclaimer )
Type:  Equity
Market:  Norway
ISIN:  NO0010650013 
S/N:  NO0010650013
  • Volume: 87,228,102
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.14 - 0.16
Bergenbio 0.15 -0.01 -3.59%

BGBIO Balance Sheet

 
Featured here, the Balance Sheet for Bergenbio ASA, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Collapse All
Period Ending: 2023
31/12
 2023
30/09
 2023
30/06
 2023
31/03
Total Current Assets 173.9 187.46 240.42 85.58
Cash and Short Term Investments 156.42 169.31 225.98 72.99
Cash - - - -
Cash & Equivalents 156.42 169.31 225.98 72.99
Short Term Investments - - - -
Total Receivables, Net 10.09 12.69 12.48 10.34
Accounts Receivables - Trade, Net - - - -
Total Inventory - - - -
Prepaid Expenses 7.39 5.46 1.96 2.25
Other Current Assets, Total 0.001 - -0.001 -
Total Assets 174.34 188 240.45 85.62
Property/Plant/Equipment, Total - Net 0.431 0.532 0.029 0.036
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net - - - -
Intangibles, Net - - - -
Long Term Investments - - - -
Note Receivable - Long Term 10.09 12.69 12.48 10.34
Other Long Term Assets, Total - - - -
Other Assets, Total -10.09 -12.69 -12.48 -10.34
Total Current Liabilities 46.86 26.73 52.41 66.63
Accounts Payable 18.6 15.1 39.91 40.47
Payable/Accrued - - - -
Accrued Expenses 28.21 11.64 12.5 26.16
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases - - - -
Other Current liabilities, Total 0.042 - -0.001 -
Total Liabilities 46.86 26.83 52.41 67.28
Total Long Term Debt - 0.101 - 0.65
Long Term Debt - 0.101 - 0.65
Capital Lease Obligations - - - -
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total - - - -
Total Equity 127.48 161.16 188.04 18.34
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 268.87 262.05 262.05 8.87
Additional Paid-In Capital 0.854 - - 35.78
Retained Earnings (Accumulated Deficit) -189.23 -147.34 -119.64 -71.73
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 46.99 46.45 45.62 45.42
Total Liabilities & Shareholders' Equity 174.34 188 240.45 85.62
Total Common Shares Outstanding 2688.69 2620.53 2620.53 88.66
Total Preferred Shares Outstanding - - - -
* In Millions of NOK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

BGBIO Comments

Write your thoughts about Bergenbio ASA
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jakub Dąda
Jakub Dąda Mar 20, 2024 4:13PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
good news! 🚀🚀🚀
Reply
0 0
Report
Ryan Mowat
Ryan Mowat Dec 14, 2020 8:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Perhaps one of the most interesting and undervalued stocks out there. 10x your moneys in 2 years may not be unrealistic. 20x your moneys in 5 years? Do your wallet a favour and take a closer look at BerGenBio. Strong cash position. Tons of independent research supporting bemcentinib as a key player in cancer survival, fibrosis treatment and as an antiviral (against covid, dengue, ebola and others). Great safety profile and well tolerated. Strong support from several BigPharma companies and leading global medical communities. Ambitious pipeline and lots more to come. Gigantic economic potential as treatment for mild and severe fibrosis (lung, liver and kidney fibrosis).
Reply
1 0
Report
Anders Rud
Anders Rud Oct 26, 2020 9:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
this Stock is going down
Reply
0 0
Report
Frank Pedersen
Frank Pedersen Sep 29, 2020 1:31PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
$BERGENBIO, OSE now is again participating in the Accord study in UK with a cure of Covid19, in parallell it is also starting test i Sout Africa for own account, and start in India is just around the corner with Bemcentinib as a Corona cure. The stock is still low priced?
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email